Joel S. Perlmutter, M.D.


Neurosciences Program

  • 314-362-6026

  • 314-362-6026

  • 314-362-0168

  • 8225

  • 2108 East Building



  • pathogenesis, neuroimaging, physiology, neurobiology, movement disorders, Parkinson disease, dystonia

  • Pharmacology, physiology and pathophysiology of basal ganglia and movement disorders

Research Abstract:

We are engaged in several studies of Parkinson Disease (PD). We investigate mechanisms of action of deep brain stimulation, a dramatic treatment for PD. These studies combine PET, cognitive testing and quantified measures of movement. We also test new drugs that might rescue injured nigrostriatal neurons (using an animal model of PD). For these, we use PET to measure dopamine pathways and also quantify motor behavior. We are developing new PET (positron emission tomography) and MR(magnetic resonance)-based neuroimaging biomarkers for measuring PD progression. We also trying to develop a PET-based method to diagnose the cause of dementia in people with PD (comparing cognitive, clinical, PET imaging and pathologic data).

We are using PET, MRI, cognitive, genetic, pathologic and clinical assessments to investigate the causes of dementia in people with Parkinson disease. We are also working on developing neuroimaging diagnostic tools for diagnosing the specific cause of dementia in individuals with PD.

We use PET to measure radioligand binding and sensorimotor processing in dystonia. We developed a new animal model of dystonia to investigate pharmacologic and physiologic changes. We use PET to investigate drug-mediated pathways in the brain and parse out the effects of selective dopaminergic agonists.

Selected Publications:

Jin H, Zhang X, Yue X, Liu H, Li J, Yang H, Flores H, Parson SM, Perlmutter JS, Tu Z. Kinetic modeling and occupancy studies of novel C-11 PET tracer for VAChT in nonhuman primates, Nucl Med Biol 43:131-9, 2016, PMCID: PMC4753027

Buddhala C, Loftin S, Kuley B, Cairns N, Perlmutter JS, Kotzbauer P. Dopaminergic, serotonergic and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol Oct;2(10):949-59, 2015 PMCID: PMC4603378

Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer P, Perlmutter JS. CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology 84:2413-21, 2015 15. PMCID: PMC4478033

Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF levels of alpha-synuclein and Aβ1-42 in Parkinson disease. Neurobiol Aging 36:476-84, 2015, PMID:25212463, PMCID: PMC4268043

Dugan L, Tian L, Quick KL, Hardt JI, Karimi M, Brown C, Loftin S, Flores H, Moerlein S, Polich J, Tabbal SD, Mink JW, Perlmutter JS. C3 provides effective neuroprotection after the onset of degeneration in a primate model of Parkinson disease Ann Neurol 76(3):393-402, 2014, PMCID: PMC4165715

Brown CA, Karimi MK, Tian L, Flores H, Su Y, Tabbal SD, Loftin SK, Moerlein SM, Perlmutter JS. Validation of midbrain PET measures for nigrostriatal neurons in macaques. Ann Neurol 74(4):602-10, 2013 [PMCID: PMC3800272

Campbell MC, Markham J, Flores H, Hartlein J, Goate A, Cairns NJ, Videen TO, Perlmutter JS. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 81(6):520-7, 2013 PMCID: PMC3775684

Karimi MK, Tian L, Brown CA, Flores HP, Loftin SK, Videen TO, Moerlein SM, Perlmutter JS: Validation of nigrostriatal positron emission tomographic measures: critical limits. Ann Neurol 73:390-6, 2013. PMCID: PMC3631302.

Hill K, Campbell M, McNeely M, Karimi M, Ushe M, Tabbal S, Hershey T, Flores H, Hartlein J, Lugar H, Revila F, Videen T, Earhart G, Perlmutter JS. Cerebral blood flow responses to dorsal and ventral STN DBS correlate with gait and balance response in Parkinson disease. Exp Neurol. 241:105-12, 2012. PMCID:PMC3570746.

Hacker C, Perlmutter JS, Criswell S, Ances B, Snyder AJ. Resting state fMRI studies of Parkinson disease. Brain 135(Pt 12):3699-711, 2012. PMCID: PMC3525055

Last Updated: 8/25/2016 11:58:24 AM

Back To Top

Follow us: